Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 63.435
Low
61.00
Averages
89.33
High
136.00
Current: 63.435
Low
61.00
Averages
89.33
High
136.00
Morgan Stanley
Maxwell Skor
Overweight
maintain
$71 -> $90
Al Analysis
2026-01-08
Reason
Morgan Stanley
Maxwell Skor
Price Target
$71 -> $90
Al Analysis
2026-01-08
maintain
Overweight
Reason
Morgan Stanley analyst Maxwell Skor raised the firm's price target on Cytokinetics to $90 from $71 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Leerink
Roanna Ruiz
Outperform
maintain
$73 -> $83
2025-12-22
Reason
Leerink
Roanna Ruiz
Price Target
$73 -> $83
2025-12-22
maintain
Outperform
Reason
Leerink analyst Roanna Ruiz raised the firm's price target on Cytokinetics to $83 from $73 and keeps an Outperform rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CYTK
Unlock Now
Truist
Srikripa Devarakonda
Buy
upgrade
$70 -> $84
2025-12-22
Reason
Truist
Srikripa Devarakonda
Price Target
$70 -> $84
2025-12-22
upgrade
Buy
Reason
Truist analyst Srikripa Devarakonda raised the firm's price target on Cytokinetics to $84 from $70 and keeps a Buy rating on the shares. Following recent approval with a differentiated label, the firm thinks MYQORZO is poised to generate significant revenue in obstructive hypertrophic cardiomyopathy. Truist has updated its model and points out worldwide peak sales for oHCM alone of $3.7B vs. $3.8B consensus. The firm anticipates a steady MYQORZO launch in early 2026 that it believes should perform at least as well as Camzyos's launch.
Morgan Stanley
NULL
to
Overweight
maintain
$65 -> $71
2025-12-22
Reason
Morgan Stanley
Price Target
$65 -> $71
2025-12-22
maintain
NULL
to
Overweight
Reason
Morgan Stanley raised the firm's price target on Cytokinetics to $71 from $65 and keeps an Overweight rating on the shares after the FDA approved the company's Myqorzo with "a differentiated label and streamlined REMS." The firm, which is "constructive" on Cytokinetics' ability to execute a strong launch, sees near-term catalysts that could drive additional upside, the analyst tells investors.
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
